Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex-specific metabolic pathways were associated with alzheimer's disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

  • Xu, Jin
  • Green, Becki|||0000-0002-0513-5188
  • Kim, Min|||0000-0002-8769-4804
  • Lord, Jodie|||0000-0003-2955-7809
  • Ebshiana, Amera
  • Westwood, Sarah|||0000-0003-0506-7813
  • Baird, Alison
  • Nevado-Holgado, Alejo|||0000-0001-9276-2720
  • Shi, Liu|||0000-0003-1752-0419
  • Hye, Abdul|||0000-0003-2237-4823
  • Snowden, Stuart|||0000-0002-9419-5819
  • Bos, Isabelle|||0000-0001-9648-6428
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • ten Kate, Mara|||0000-0002-8290-8543
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gabel, Silvy
  • Meersmans, Karen
  • Blin, Olivier
  • Richardson, Jill|||0000-0001-6564-3187
  • De Roeck, Ellen
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Bordet, Régis|||0000-0003-3916-6422
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Kettunen, Petronella|||0000-0002-2510-3423
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Verhey, Frans R. J.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Peyratout, Gwendoline
  • Tainta, Mikel|||0000-0003-0624-1211
  • Johannsen, Peter
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Froelich, Lutz|||0000-0003-1494-0813
  • Dobricic, Valerija|||0000-0001-8559-1097
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Wallin, Anders|||0000-0001-9506-0513
  • Popp, Julius|||0000-0002-0068-0312
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Bertram, Lars|||0000-0002-0108-124X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Streffer, Johannes Rolf|||0000-0002-9387-5951
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Lovestone, Simon|||0000-0003-0473-4565
  • Proitsi, Petroula|||0000-0002-2553-6974
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives. Methods: We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, cerebrospinal fluid (CSF) biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, APOE ε4 stratification and assessment of metabolites' discriminatory performance in AD. Results: In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (area under curve (AUC) = 0.83, standard error (SE) = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046). Conclusions: metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, were associated to females, paving the way to personalised treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

  • Gobom, Johan|||0000-0001-6193-6193
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Vyhnalek, Martin
  • Gauthier, Serge
  • Cataldi, Samuela
  • Lerch, Ondrej
  • Laczo, Jan
  • Cechova, Katerina
  • Clarin, Marcus
  • Benet, Andrea L.
  • Pascoal, Tharick A.
  • Rahmouni, Neserine
  • Vandijck, Manu
  • Huyck, Else
  • Le Bastard, Nathalie
  • Stevenson, Jenna
  • Chamoun, Mira
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Andreasson, Ulf
  • Verbeek, Marcel M.
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Rinaldi, Roberta
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Sheardova, Katerina
  • Hort, Jakub|||0000-0002-1080-3726
  • Blennow, Kaj|||0000-0002-1890-4193
Objectives: The core cerebrospinal fluid (CSF) biomarkers; total tau (tTau), phospho-tau (pTau), amyloid β 1-42 (Aβ 1-42), and the Aβ 1-42/Aβ 1-40 ratio have transformed Alzheimer's disease (AD) research and are today increasingly used in clinical routine laboratories as diagnostic tools. Fully automated immunoassay instruments with ready-to-use assay kits and calibrators has simplified their analysis and improved reproducibility of measurements. We evaluated the analytical performance of the fully automated immunoassay instrument LUMIPULSE G (Fujirebio) for measurement of the four core AD CSF biomarkers and determined cutpoints for AD diagnosis. Methods: Comparison of the LUMIPULSE G assays was performed with the established INNOTEST ELISAs (Fujirebio) for hTau Ag, pTau 181, β-amyloid 1-42, and with V-PLEX Plus Aβ Peptide Panel 1 (6E10) (Meso Scale Discovery) for Aβ 1-42/Aβ 1-40, as well as with a LC-MS reference method for Aβ 1-42. Intra- and inter-laboratory reproducibility was evaluated for all assays. Clinical cutpoints for Aβ 1-42, tTau, and pTau was determined by analysis of three cohorts of clinically diagnosed patients, comprising 651 CSF samples. For the Aβ 1-42/Aβ 1-40 ratio, the cutpoint was determined by mixture model analysis of 2,782 CSF samples. Results: The LUMIPULSE G assays showed strong correlation to all other immunoassays (r.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset

  • Homann, Jan
  • Osburg, Tim
  • Ohlei, Olena
  • Dobricic, Valerija|||0000-0001-8559-1097
  • Deecke, Laura
  • Bos, Isabelle|||0000-0001-9648-6428
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Gabel, Silvy
  • Scheltens, Philip|||0000-0002-1046-6408
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Blin, Olivier
  • Richardson, Jill|||0000-0001-6564-3187
  • Bordet, Régis|||0000-0003-3916-6422
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Popp, Julius|||0000-0002-0068-0312
  • Clark, Christopher|||0000-0001-7210-7702
  • Peyratout, Gwendoline
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Tainta, Mikel|||0000-0003-0624-1211
  • Dobson, Richard James Butler|||0000-0003-4224-9245
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Wittig, Michael
  • Franke, Andre|||0000-0003-1530-5811
  • Lill, Christina|||0000-0002-2805-1307
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lovestone, Simon|||0000-0003-0473-4565
  • Streffer, Johannes Rolf|||0000-0002-9387-5951
  • ten Kate, Mara|||0000-0002-8290-8543
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Bertram, Lars|||0000-0002-0108-124X
Alzheimer's disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, aging populations. AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade. Most of these GWAS used dichotomized clinical diagnostic status, i.e., case vs. control classification, as outcome phenotypes, without the use of biomarkers. An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work. Specifically, we utilized genotype and phenotype data from n = 931 individuals collected under the auspices of the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study to perform a total of 19 separate GWAS analyses. As outcomes we used five magnetic resonance imaging (MRI) traits and seven cognitive performance traits. For the latter, longitudinal data from at least two timepoints were available in addition to cross-sectional assessments at baseline. Our GWAS analyses revealed several genome-wide significant associations for the neuropsychological performance measures, in particular those assayed longitudinally. Among the most noteworthy signals were associations in or near EHBP1 (EH domain binding protein 1; on chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall as well as SMOC2 (SPARC related modular calcium binding 2; 6p27) with immediate recall in a memory performance test. On the X chromosome, which is often excluded in other GWAS, we identified a genome-wide significant signal near IL1RAPL1 (interleukin 1 receptor accessory protein like 1; Xp21.3). While polygenic score (PGS) analyses showed the expected strong associations with SNPs highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not show noteworthy associations with recent AD risk GWAS findings. In summary, our study highlights the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and nominates several new loci not previously implicated in cognitive decline.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

  • Jansen, Iris E.|||0000-0003-1901-8131
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Gomez-Fonseca, Duber
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Grenier-Boley, Benjamin
  • Zettergren, Anna|||0000-0002-7182-8417
  • Mishra, Aniket|||0000-0002-8141-1543
  • Ali, Muhammad|||0000-0002-1399-6631
  • Andrade, Victor|||0000-0003-0682-269X
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Kleineidam, Luca
  • Küçükali, Fahri
  • Sung, Ju Sung
  • Tesí, Niccolo
  • Vromen, Ellen|||0000-0001-7774-5500
  • Wightman, Douglas P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Athanasiu, Lavinia
  • Bahrami, Shahram
  • Bailly, Henri
  • Belbin, Olivia|||0000-0002-6109-6371
  • Bergh, Sverre|||0000-0001-9593-2967
  • Bertram, Lars|||0000-0002-0108-124X
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Boada, Mercè|||0000-0003-2617-3009
  • Boland, Anne|||0000-0001-8789-5676
  • Buerger, K.
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Chene, Geneviève|||0000-0002-8368-6460
  • Claassen, Jurgen|||0000-0002-1778-8151
  • Debette, Stéphanie|||0000-0001-8675-7968
  • Deleuze, Jean-Francois
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Dufouil, Carole|||0000-0003-2442-4476
  • Duron, Emmanuelle
  • Düzel, Emrah
  • Fladby, Tormod|||0000-0002-9984-9797
  • Fortea, Juan|||0000-0002-1340-638X
  • Froelich, Lutz|||0000-0003-1494-0813
  • García-González, Pablo|||0000-0003-0125-5403
  • Garcia-Martinez, María
  • Giegling, Ina
  • Goldhardt, Oliver
  • Gobom, Johan|||0000-0001-6193-6193
  • Grimmer, Timo
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Hampel, Harald
  • Hanon, Olivier|||0000-0002-4697-122X
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Helisalmi, Seppo
  • Heneka, Michael|||0000-0003-4996-1630
  • Hernández, Isabel|||0000-0001-8119-393X
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Holstege, Henne|||0000-0002-7688-3087
  • Jarholm, Jonas
  • Kern, Silke
  • Knapskog, Anne-Brita
  • Koivisto, A.M.
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • Lage, Carmen|||0000-0003-1703-121X
  • Laske, Christoph
  • Leinonen, Ville|||0000-0002-4282-4687
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Lleó, Alberto|||0000-0002-2568-5478
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • López-Garcia, Sara
  • Maier, Wolfgang
  • Marquié, Marta|||0000-0002-0660-0950
  • Mol, Merel O.|||0000-0003-2533-2530
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Moreno, Fermin|||0000-0001-5200-3164
  • Moreno-Grau, Sonia
  • Nicolas, Gael|||0000-0001-9391-7800
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Pålhaugen, Lene
  • Papma, Janne M.
  • Pasquier, Florence|||0000-0001-9880-9788
  • Perneczky, Robert|||0000-0003-1981-7435
  • Peters, Oliver|||0000-0003-0568-2998
  • Pijnenburg, Yolande A.L.
  • Popp, Julius|||0000-0002-0068-0312
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Pozueta, Ana
  • Priller, Josef|||0000-0001-7596-0979
  • Puerta, Raquel|||0000-0002-1191-5893
  • Quintela, Inés|||0000-0002-0239-7975
  • Ramakers, Inez
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Scheltens, Philip|||0000-0002-1046-6408
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Schmid, Matthias
  • Schneider, Anja|||0000-0001-9540-8700
  • Selbæk, Geir|||0000-0001-6511-8219
  • Selnes, Per
  • Shadrin, Alexey
  • Skoog, Ingmar
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Teipel, Stefan
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • van Swieten, John C.
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Waern, Margda|||0000-0002-8330-6915
  • Wagner, Michael
  • Wiltfang, Jens W.
  • Wittens, Mandy M.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Zulaica, Miren
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Bjerke, Maria
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Jessen, Frank
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Pastor, Pau|||0000-0002-7493-8777
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.